Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
To determine what side effects and what clinical effect, if any, the administration of this
investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is
approved by the United States Food and Drug Administration (FDA) to treat patients with
relapsed or refractory follicular NHL], has in this patient population.